[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] SARS-coV-2: an updated review highlighting its evolution and treatments
X Zhang, H Yuan, Z Yang, X Hu, YS Mahmmod, X Zhu… - Vaccines, 2022 - mdpi.com
Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide
have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The …
have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The …
[HTML][HTML] Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)
T Siripongboonsitti, M Muadchimkaew, K Tawinprai… - Scientific Reports, 2023 - nature.com
This study aimed to evaluate the efficacy of favipiravir (FPV) in preventing the development
of severe COVID-19 in patients with mild-to-moderate symptoms. The study evaluated 1037 …
of severe COVID-19 in patients with mild-to-moderate symptoms. The study evaluated 1037 …
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy …
T Siripongboonsitti, N Nontawong… - Microbiology …, 2023 - Am Soc Microbiol
The effectiveness of neutralizing monoclonal antibodies against emerging variants with
spike protein mutations has been limited. Early high-titer convalescent plasma therapy …
spike protein mutations has been limited. Early high-titer convalescent plasma therapy …
Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza
FG Hayden, RP Lenk, C Epstein… - The Journal of Infectious …, 2023 - academic.oup.com
Background The pharmacokinetics of oral favipiravir and the relationships of plasma
concentrations to antiviral effects are incompletely studied in influenza. Methods Serial …
concentrations to antiviral effects are incompletely studied in influenza. Methods Serial …
[HTML][HTML] Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized …
Background While favipiravir had been the standard anti-SARS-CoV-3 drug for COVID-19
treatment in Thailand, the efficacy of favipiravir treatment is controversial. Andrographis …
treatment in Thailand, the efficacy of favipiravir treatment is controversial. Andrographis …
[HTML][HTML] Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
V Luvira, WHK Schilling, P Jittamala, JA Watson… - BMC Infectious …, 2024 - Springer
Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …
[HTML][HTML] Quantum DFT studies on the drug delivery of favipiravir using pristine and functionalized chitosan nanoparticles
S Ataei, E Nemati-Kande, A Bahrami - Scientific Reports, 2023 - nature.com
Considering the spread of the COVID-19 pandemic, finding new drugs along with the
development of effective drug delivery methods can help in the treatment of this disease. For …
development of effective drug delivery methods can help in the treatment of this disease. For …
Statistical challenges when analyzing SARS-CoV-2 RNA measurements below the assay limit of quantification in COVID-19 clinical trials
CB Moser, KW Chew, MJ Giganti, JZ Li… - The Journal of …, 2023 - academic.oup.com
Most clinical trials evaluating coronavirus disease 2019 (COVID-19) therapeutics include
assessments of antiviral activity. In recently completed outpatient trials, changes in nasal …
assessments of antiviral activity. In recently completed outpatient trials, changes in nasal …
[HTML][HTML] Overview of antiviral drug therapy for COVID-19: where do we stand?
R Esposito, D Mirra, L Sportiello, G Spaziano… - Biomedicines, 2022 - mdpi.com
The vaccine weapon has resulted in being essential in fighting the COVID-19 outbreak, but it
is not fully preventing infection due to an alarming spreading of several identified variants of …
is not fully preventing infection due to an alarming spreading of several identified variants of …